PARProceedings of Anticancer Research2208-35452208-3553Bio-Byword Scientific Publishing Pty. Ltd.10.26689/par.v9i5.12268ArticleComparative Study on the Diagnosis of Thoracic Wall and Rib Involvement in Lung Adenocarcinoma Using 99mTc-MDP SPECT/CT and MSCThttps://artdesignp.com/journal/PAR/9/5/10.26689/par.v9i5.12268ZhaWenjin,LiQiaoying2025952025-10-16Objective: To compare the diagnostic value of 99mTc-MDP SPECT/CT and MSCT in detecting thoracic wall and rib involvement in lung adenocarcinoma. Methods: A retrospective analysis was conducted on the imaging data of 78 thoracic wall and rib lesions from 66 patients, a total of 32 males and 34 females, aged (53.2 ± 5.6) years old with pathologically confirmed lung adenocarcinoma who underwent both 99mTc-MDP SPECT/CT and MSCT examinations from March 2017 to September 2023. The diagnostic efficacy of the two imaging modalities was compared using pathological confirmation or clinical follow-up as the gold standard. Results: Pathological confirmation or clinical follow-up revealed 74 lesions with thoracic wall bone involvement in lung adenocarcinoma (20 lesions confirmed by surgical pathology and 54 lesions confirmed by clinical follow-up) and 4 lesions without thoracic wall or rib involvement (2 lesions confirmed by surgical pathology and 2 lesions confirmed by clinical follow-up). The diagnostic sensitivity, specificity, and accuracy of 99mTc-MDP SPECT/CT were 97.3%, 50.0%, and 94.9%, respectively. Its diagnostic sensitivity and accuracy were higher than those of MSCT (72.3% and 74.4%, respectively), with statistically significant differences (P < 0.05). The specificity of 99mTc-MDP SPECT/CT was lower than that of MSCT (100.0%), but the difference was not statistically significant (P < 0.05). There were no statistically significant differences in the positive predictive value and negative predictive value between 99mTc-MDP SPECT/CT and MSCT (P > 0.05). 99mTc-MDP SPECT/CT examination revised the MSCT tumor staging in 14 patients [21.2% (14/66)] with lung adenocarcinoma. Conclusion: 99mTc-MDP SPECT/CT imaging demonstrates superior diagnostic efficacy compared to MSCT in detecting thoracic wall and rib involvement in lung adenocarcinoma. It offers more accurate tumor staging than MSCT, and an accurate diagnosis aids in clinical treatment decision-making.

Sun X, Liu Z, Yang D, et al., 2024, The Application Value of 18F-FDG PET Radiomics in Preoperative Prediction of Vascular Invasion and Visceral Pleural Invasion in Lung Adenocarcinoma. Chinese Journal of Nuclear Medicine and Molecular Imaging, 44(2): 74–79.

Paula A, Vanessa J, Dorothy J, et al., 2024, Completeness of Resection and Long-Term Survival of Patients Undergoing Resection for Pathologic T3 Non-Small Cell Lung Cancer: An International Association for the Study of Lung Cancer Analysis. Journal of Thoracic Oncology, 19(1): 141–152.

Mazzella A, Loi M, Alifano M, et al., 2020, Prognostic Factors of Resected Lung Cancer with Chest Wall Involvement. Current Challenges in Thoracic Surgery, 2: 61–68.

Zhao Y, Wang W, Liang H, et al., 2019, The Optimal Treatment for Stage IIIA-N2 Non-Small Cell Lung Cancer: A Network Meta-Analysis. Annals of Thoracic Surgery, 107: 1866–1875.

Wei L, Zhou Y, 2022, A Comparative Study of CT and MRI Based on the Eighth Edition of TNM Staging for Non-Small Cell Lung Cancer. Journal of Medical Imaging, 32(5): 774–777.

Kapsoritakis N, Stathaki M, Bourogianni O, et al., 2021, Clinical Impact of Targeted Single-Photon Emission Computed Tomography/Computed Tomography (SPECT/CT) Bone Scintigraphy on the Assessment of Bone Metastasis in Cancer Patients. Nuclear Medicine Communications, 42(11): 1202–1208.

Qingchun Z, Zhao Z, 2020, Diagnostic Value of SPECT/CT Fusion Imaging for Sacral Lesions. Chinese Journal of Medical Imaging, 28(8): 622–625.

Sun W, Wang G, Wang X, et al., 2021, Application of SPECT/Low-Dose CT Fusion Imaging Technology in the Diagnosis of Bone Metastases from Lung Cancer. Journal of Medical Imaging, 31(2): 327–330.

Ding Y, Shi D, Zhu Z, et al., 2017, Exploration of the Diagnostic Value of SPECT/CT Bone Tomographic Fusion Imaging for Bone Metastases from Tumors. Journal of Medical Imaging, 27(3): 527–530.

Su Y, Huang L, Xie L, et al., 2019, Application Value of 99mTc-MDP SPECT/CT Tomographic Fusion Imaging in Differentiating Benign and Malignant Spinal Lesions. Journal of Clinical Radiology, 38(11): 2144–2147.

Tanaka K, Norikane T, Mitamura K, et al., 2022, Quantitative [99mTc]Tc-MDP SPECT/CT Correlated with [18F]NaF PET/CT for Bone Metastases in Patients with Prostate Cancer. EJNMMI Physics, 9: 8301–8310.

Wang Q, Dong L, Liu L, et al., 2020, Value of Combined SPECT and MR Examinations in the Early Diagnosis of Bone Metastases from Malignant Tumors. Imaging Research and Medical Applications, 4(19): 205–206.

Chen M, Wang Y, Jiang X, et al., 2019, Study on the Diagnostic Value of SPECT Combined with MDCT and MRI Multimodal Imaging for Bone Metastases. Journal of Medical Imaging, 29(12): 2121–2125.

Dong K, Lou J, Liu J, et al., 2014, Diagnostic Value of SPECT/CT Fusion Imaging for Chest Wall Bone Invasion in Lung Cancer. Chinese Journal of Clinical Medical Imaging, 25(5): 332–335.

Zhang X, Xiao G, Kong B, et al., 2017, Differential Diagnostic Value of SPECT/CT Same-Machine Fusion Imaging for Solitary Spinal Lesions. Journal of Oncology, 23(10): 890–894.